Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €182.36 EUR
Change Today +1.07 / 0.59%
Volume 705.0
BVF On Other Exchanges
New York
As of 10:40 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (BVF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/15 - €194.80
52 Week Low
08/8/14 - €78.82
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

valeant pharmaceuticals inte (BVF) Details

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, as well as Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer. It also provides Zovirax, an antiviral for recurrent herpes labialis and initial genital herpes; Syprine to treat patients with Wilson's disease; Elidel to treat atopic dermatitis; Prolensa for inflammation and pain following cataract surgery; Duromine, a weight loss drug; and Lotemax gel for post-operative inflammation and pain. In addition, the company offers PreserVision, an antioxidant eye vitamin and mineral supplement; CeraVe to rebuild and repair the skin barrier; ReNu Multiplus to lubricate and rewet soft contact lenses; Biotrue for healthy contact lens wear; Ocuvite, a lutein eye vitamin and mineral supplement; Boston, a cleansing solution for gas permeable contact lenses; Artelac to treat dry eyes; AntiGrippin for acute respiratory and respiratory viral diseases, and influenza; and Bedoyecta, a vitamin B complex product. Further, it provides SofLens daily disposable contact lenses; PureVision, a contact lens; various ophthalmic surgical products; Biotrue ONEday lens; medical device systems for aesthetic applications; and Bausch + Lomb Ultra, a contact lens. Additionally, the company offers Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; Cardizem CD to treat hypertension and angina; and Latanoprost for the treatment of glaucoma. Valeant Pharmaceuticals International, Inc. was founded in 1983 and is headquartered in Laval, Canada.

16,800 Employees
Last Reported Date: 02/25/15
Founded in 1983

valeant pharmaceuticals inte (BVF) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.8M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $1.0M
Chief Legal Officer, Head of Corporate & Busi...
Total Annual Compensation: $750.0K
Executive Vice President and Company Group Ch...
Total Annual Compensation: $511.1K
Compensation as of Fiscal Year 2013.

valeant pharmaceuticals inte (BVF) Key Developments

Pershing To Hold Discussion With Valeant For Acquisitions

Pershing Square Capital Management, L.P. raises stake in Valeant Pharmaceuticals International, Inc. (TSX:VRX). Pershing expect to conduct discussions with Valeant and other relevant parties regarding strategic acquisitions by or joint ventures with Valeant, or other similar arrangements. These discussions would be exploratory in nature and there is no assurance that they would lead to a definitive transaction.

Valeant Pharmaceuticals International Mulls Acquisitions

Valeant Pharmaceuticals International, Inc. (TSX:VRX) has filed a follow-on equity offering in the amount of $1450 million and intends to use the proceeds for general corporate purposes, including acquisitions and debt repayments.

Valeant Pharmaceuticals International Inc. Prices Four-Part Offering of High-Yield Bonds

Valeant Pharmaceuticals International Inc. announced that it has priced a four-part offering of high-yield bonds totaling $10.1 billion for its proposed $14.5 billion acquisition of Salix Pharmaceuticals. The $10.1 billion senior unsecured notes offering by Valeant is the high-yield deal on record. The notes comprise two eight-year dual-currency tranches and a 10-year tranche. Valeant also said the notes offering has been upsized to about $10.1 billion from the previously announced $9.6 billion. As a result of the increased size of the notes offering, Valeant intends to incur $400 million less in incremental term loans in connection with Salix deal. Valeant said it expects to close the notes offering on or about March 27.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BVF:GR €182.36 EUR +1.07

BVF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,950 JPY -27.50
Eisai Co Ltd ¥8,803 JPY -115.00
Mylan NV $61.87 USD -0.015
Perrigo Co PLC $165.95 USD +1.63
Sun Pharmaceutical Industries Ltd 1,011 INR -16.50
View Industry Companies

Industry Analysis


Industry Average

Valuation BVF Industry Range
Price/Earnings 73.2x
Price/Sales 8.0x
Price/Book 12.3x
Price/Cash Flow 27.5x
TEV/Sales 6.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at